Indaptus Therapeutics (INDP) Total Liabilities (2020 - 2026)
Indaptus Therapeutics (INDP) posted quarterly Total Liabilities of $2.2 million for Q1 2026, down 59.7% year-over-year from $5.4 million in Q1 2025, and down 76.58% quarter-over-quarter from $9.3 million in Q4 2025.
Indaptus Therapeutics (INDP) Total Liabilities (2020 - 2026) Analysis & Trends
Indaptus Therapeutics' Total Liabilities history runs 7 years deep, the most recent figure standing at $2.2 million for Q1 2026.
- In Q1 2026, Total Liabilities fell 59.7% year-over-year to $2.2 million; the TTM figure through Mar 2026 stood at $2.2 million (down 59.7% YoY), while the FY2025 annual figure was $9.3 million, up 174.32% from the prior year.
- Total Liabilities for Q1 2026 stood at $2.2 million, down from $9.3 million in the prior quarter.
- The five-year high for Total Liabilities was $9.3 million in Q4 2025, with the low at $1.6 million in Q1 2024.
- The 5-year median for Total Liabilities is $2.9 million (2022), against an average of $3.7 million.
- The sharpest annual moves came in 2022 and 2025: Total Liabilities slumped 93.42% in 2022, then soared 249.72% in 2025.
- Indaptus Therapeutics' Total Liabilities stood at $3.4 million in 2022, then dropped by 17.07% to $2.8 million in 2023, then increased by 19.19% to $3.4 million in 2024, then soared by 174.32% to $9.3 million in 2025, then tumbled by 76.58% to $2.2 million in 2026.
- Business Quant data shows INDP's Total Liabilities at $2.2 million in Q1 2026, $9.3 million in Q4 2025, and $6.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 10.03 Bn |
| 10 | Indaptus Therapeutics | 146.91 Mn | 135.35 Mn | - | 615,426.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 615,426.00 |
| Mar 31, 2026 | 2.18 Mn |
| Dec 31, 2025 | 9.31 Mn |
| Sep 30, 2025 | 6.84 Mn |
| Jun 30, 2025 | 6.84 Mn |
| Mar 31, 2025 | 5.41 Mn |
| Dec 31, 2024 | 3.39 Mn |
| Sep 30, 2024 | 2.24 Mn |
| Jun 30, 2024 | 1.96 Mn |
| Mar 31, 2024 | 1.59 Mn |
| Dec 31, 2023 | 2.85 Mn |
| Sep 30, 2023 | 2.46 Mn |
| Jun 30, 2023 | 2.22 Mn |
| Mar 31, 2023 | 1.96 Mn |
| Dec 31, 2022 | 3.43 Mn |
| Sep 30, 2022 | 2.89 Mn |
| Jun 30, 2022 | 3.65 Mn |
| Mar 31, 2022 | 3.73 Mn |
| Dec 31, 2021 | 4.68 Mn |
| Sep 30, 2021 | 43.86 Mn |